Many thanks @Hadrian for sharing this link to the Gedeon Rechter investor webinar.
I just had a chance to listen to it today.
A few more points to add to Hadrian's excellent list above.
The candour from the three GR executives was indeed refreshing. It sounded like the acquisition transaction was a nightmare with so many aggrieved parties on the other side swirling around Mithra trying to claw back any value to satisfy debts and other obligations.
The GR CEO said that GR only had to pay minimal cash to get what they wanted.
The GR CEO said the success of the transaction was to get hold of Drovelis(EU name)/Nextstellis (US and Aust name). He also said any benefit from Donesta, the menopause product, was pure upside. GR only need to get the Nextstellis gains to make the overall transaction a success.
If anybody can attend the half year GR results webinar it should have a Mithra-Neststellis update which could be helpful for MYX shareholders to understand.
MYX Price at posting:
$4.40 Sentiment: Buy Disclosure: Held
